Superantigen-induced cytokine release from whole-blood cell culture as a functional measure of drug efficacy after oral dosing in nonhuman primates

Research in Veterinary Science

Volumn 83, Issue 2, 2007, Pages 182-187

  Krakauer, Teresa ^a   Stephens, Julie ^a   Buckley, Marilyn ^a   Tate, Mallory ^b  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Cytokines; Pentoxifylline; Whole blood cell culture

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; PENTOXIFYLLINE; STAPHYLOCOCCUS ENTEROTOXIN B; SUPERANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE TIME EFFECT RELATION; DRUG DOSE INCREASE; DRUG EFFICACY; EX VIVO STUDY; NONHUMAN; RHESUS MONKEY; SEPTIC SHOCK;

ADMINISTRATION, ORAL; ANIMALS; BLOOD CELLS; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROTOXINS; MACACA MULATTA; PENTOXIFYLLINE; SUPERANTIGENS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; BACTERIA (MICROORGANISMS); MACACA MULATTA; PRIMATES;

EID: 34250820502     PISSN: 00345288     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rvsc.2006.12.004     Document Type: Article

References (30)

1. Baker M.D., and Acharya K.A. Superantigens: structure, function, and diversity. In: Krakauer T. (Ed). Superantigen Protocols (2003), Humana Press, Totowa 1-31
2. Bell S.G. Immunomodulation, part I: pentoxifylline. Neonatal Network 24 (2005) 45-48
3. Blank C., Luz A., Bendigs S., Erdmann A., Wagner H., and Heeg K. Superantigen and endotoxin synergize in the induction of lethal shock. European Journal of Immunology 27 (1997) 825-833
4. Choi Y., Kotzin B., Hernon L., Callahan J., Marrack P., and Kappler J. Interaction of Staphylococcus aureus toxin "superantigens" with human T cells. Proceedings of National Academy of Sciences USA 86 (1989) 8941-8945
5. Darenberg J., Soderquist B., Normark B.H., and Norrby-Teglund A. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clinical Infectious Diseases 38 (2004) 836-842
6. Fraser J., Newton M., and Weiss A. CD28 and T-cell antigen receptor signal transduction coordinately regulates interleukin 2 gene expression in response to superantigen stimulation. Journal of Experimental Medicine 175 (1992) 1131-1134
7. Fraser J., Arcus V., Kong P., Baker E., and Proft T. Superantigens - powerful modifiers of the immune system. Molecular Medicine Today 3 (2000) 125-132
8. Geller-Hong E., and Gupta G. Therapeutic approaches to superantigen-based diseases: a review. Journal of Molecular Recognition 16 (2003) 91-101
9. Hodoval L.F., Morris E.L., Crawley G.J., and Beisel W.R. Pathogenesis of lethal shock after intravenous staphylococcal enterotoxin B in monkeys. Applied Microbiology 16 (1968) 187-192
10. Kotzin B.L., Leung D.Y.M., Kappler J., and Marrack P. Superantigens and their potential role in human disease. Advances in Immunology 54 (1993) 99
11. Krakauer T. Inhibition of toxic shock syndrome toxin-induced cytokine production and T cell activation by interleukin 10, interleukin 4, and dexamethasone. Journal of Infectious Diseases 172 (1995) 988
12. Krakauer T. Immune response to staphylococcal superantigens. Immunological Research 20 (1999) 163-173
13. Krakauer T. Chemotherapeutics targeting immune activation by staphylococcal superantigens. Medical Science Monitor 11 (2005) 290-295
14. Krakauer T., and Stiles B.G. Pentoxifylline inhibits superantigen-induced toxic shock and cytokine release. Clinical Diagnostic Laboratory Immunology 6 (1999) 594-598
15. Krakauer T., and Stiles B.G. Staphylococcal and streptococcal superantigens. In: Swearengen J.R. (Ed). Biodefense Research Methodology and Animal Models (2006), Taylor and Francis Publishers, Boca Raton 291-391
16. Krakauer T., Vilcek J., and Oppenheim J.J. Proinflammatory cytokines: TNF and IL-1 families, chemokines, TGFβ and others. In: Paul W. (Ed). Fundamental Immunology (1998), Lippincott-Raven Publishers, Philadelphia 775-811
17. McCormick J.K., Yarwood J.M., and Schlievert P.M. Toxic shock syndrome and bacterial superantigens: an update. Annual Review of Microbiology 55 (2001) 77
18. Miethke T., Wahl C., Heeg K., Echtenacher B., Krammer P.H., and Wagner H. T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. Journal of Experimental Medicine 175 (1992) 91-98
19. Miethke T., Wahl C., Heeg K., Echtenacher B., Krammer P.H., and Wagner H. Superantigen mediated shock: a cytokine release syndrome. Immunobiology 189 (1993) 270-284
20. Mollick J.A., Chintagumpala M., Cook R.G., and Rich R.R. Staphylococcal exotoxin activation of T cells: role of exotoxin-MHC class II binding affinity and class II isotype. Journal of Immunology 146 (1991) 436-468
21. Neuner P., Klosner G., Schauer E., Pourmojib M., Macheiner W., Grunwald C., Knobler A., Schwarz A., Luger T.A., and Schwarz T. Pentoxifylline in vivo down-regulates the release of IL-1β, IL-6, IL-8 and tumour necrosis factor-α by human peripheral blood mononuclear cells. Immunology 83 (1994) 262-267
22. Parsonnet J. Mediators in the pathogenesis of toxic shock syndrome: overview. Review of Infectious Diseases 11 (1989) S263-S269
23. Proft T., and Fraser J.D. Bacterial superantigens. Clinical and Experimental Immunology 133 (2003) 299-306
24. Rajagopalan G., Sen M.M., and David C.S. In vitro and in vivo evaluation of staphylococcal superantigen peptide antagonists. Infection and Immunity 72 (2004) 6733-6737
25. Regensteiner J.G., and Hiatt W.R. Current medical therapies for patients with peripheral arterial disease: a critical review. American Journal of Medicine 112 (2002) 49-57
26. Stiles B.G., Bavari S., Krakauer T., and Ulrich R.G. Toxicity of staphylococcal enterotoxins potentiated by lipopolysaccharide: major histocompatibility complex class II molecule dependency and cytokine release. Infection and Immunity 61 (1993) 5333-5338
27. Stiles B.G., Campbell Y.G., Castle R.M., and Grove S.A. Correlation of temperature and toxicity in murine studies of staphylococcal enterotoxins and toxic shock syndrome toxin 1. Infection and Immunity 67 (1999) 1521-1525
28. Trede N.S., Geha R.S., and Chatila T. Transcriptional activation of IL-1 beta and tumor necrosis factor-alpha genes by MHC class II ligands. Journal of Immunology 146 (1991) 2310-2315
29. Visvanathan K., Charles A., Bannan J., Pugach P., Kashfi K., and Zabriskie J.B. Inhibition of bacterial superantigens by peptides and antibodies. Infection and Immunity 69 (2001) 875-884
30. Whitehouse M.W. Anti-TNF-alpha therapy for chronic inflammation: reconsidering pentoxifylline as an alternative to therapeutic protein drugs. Immunopharmacology 12 (2004) 211-217